INTRODUCTION

5-aza-2'-deoxycytidine (decitabine) is a cytosine analogue with clinical activity in myelodysplastic syndromes (MDS)
1 and other myeloid leukemias 2, 3 . Both in vivo and in vitro, decitabine induces global and gene specific DNA hypomethylation 3, 4 .
DNA methylation is an epigenetic modification of DNA that has a role in the control of gene expression 5 . Aberrant DNA methylation of promoter associated
CpG islands is frequent in leukemias 6, 7 . By inactivating genes important for cell function, aberrant DNA methylation is considered a functional equivalent to the genetic disruption of these genes. It is postulated that reversal of abnormal methylation patterns, that characterize a significant subset of patients with leukemia 6, 7 , may result in the reactivation of aberrantly silenced genes and in suppression of the malignant leukemic clone.
Nucleosome-associated histone tails can undergo several changes in their biochemical composition, including acetylation. The biochemical composition of these tails is associated with specific gene activation states 8 . For instance, acetylation of specific residues in histone H3 and H4 is associated with an open chromatin configuration and gene transcription. In contrast, deacetylation of these residues is associated with a repressive state 8 . These changes in histone acetylation are mediated by enzymes with histone acetylase and deacetylase activity 9 , and are therefore reversible. Inhibition of deacetylase activity results in accumulation of histone acetylation and a permissive gene expression state 10 . To exploit this phenomenon clinically, biochemical compounds with histone deacetylase inhibitory activity, of which valproic acid (VPA) is one, are being only.
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DNA methylation of promoter associated CpG islands and modifications in the biochemical composition of nucleosome-associated histone tails cooperate in the control of gene expression 16 . It is it not currently known which alteration is dominant, but in most instances the combination of a hypomethylating agent with a histone deacetylase inhibitor (HDACI) results in enhanced gene reactivation 17 .
We previously studied the cellular and molecular effects of the combination of decitabine with VPA in leukemia cell lines and demonstrated this combination to have synergistic antileukemia activity in a sequence independent manner 18 .
Based on this information, we designed a phase I/II clinical trial to evaluate the safety, clinical efficacy, and molecular consequences of the combination of decitabine and VPA in patients with leukemia.
MATERIAL AND METHODS
Study Group
Eligibility criteria differed between the phase I and II portions of the study. For the phase I, patients with acute or chronic leukemia and MDS were eligible. The phase II was restricted to patients with acute myelogenous leukemia (AML) or high-risk MDS (bone marrow blasts ≥ 10%). Untreated patients older than 60 years of age with AML or MDS who refused or were not candidates for frontline chemotherapy were eligible for both phases of the study. Whether a patient was a candidate for intensive chemotherapy was determined by the treating physician only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From after discussion with the patient. Other inclusion criteria were: age older than 2 years; performance status < 2 (ECOG scale), and adequate liver and renal functions. Patients must had been off chemotherapy for 2 weeks prior to entering this study, although the use of hydroxyurea for patients with proliferative disease was allowed during the first two weeks on therapy. Patients were asked to continue birth control for the duration of the trial. Nursing and pregnant females were excluded, as well as patients with active and uncontrolled infections, or illnesses, evidence of a history of hepatitis B, or C, alcoholic liver disease or hepatopathy. Patients already receiving VPA were also excluded. All patients signed informed consent following institutional guidelines. Approval was obtained from the University of Texas MD Anderson Cancer Center institutional review board for these studies.
Treatment
Treatment varied depending on whether a patient was treated in the phase I or II portions of the study. In both phases, a fixed low dose of decitabine, 15 mg/m 2 IV daily infused over 1 hour for 10 consecutive days, was administered. This dose was selected as the optimal dose in a prior phase I study of single agent decitabine 2 . VPA was administered orally in two or three divided doses (depending on the total dose) daily for 10 days on the same days as decitabine.
In the phase I, three dose levels of VPA were studied: 20, 35 and 50 mg/kg orally daily for 10 days. The doses of VPA were calculated based on prior data indicating that the optimal dose of single agent VPA that induces maximal acetylation is around 20 to 30 mg/kg 18 . In the phase II, the combination of only.
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Response criteria and statistical methods
A complete response (CR) required the disappearance of all signs and symptoms related to disease, normalization of peripheral counts with an absolute neutrophil count ≥10 9 /L, platelet count ≥100 x 10 9 /L, and a bone marrow with ≤ 5% blasts. A CRp was defined as a CR except for a platelet count increase by 50% to above 30 x 10 9 /L but <100 x 10 9 /L. Remission duration was calculated from date of first response until relapse, and survival from start of therapy until death from any cause.
In the phase I, cohorts of 3 patients were entered at each dose level. If one patient developed grade 3 or higher non-hematological toxicity, three more patients were accrued at that dose level. If two or more patients developed grade 3 or higher non-hematological toxicity, the dose of VPA was considered toxic.
The MTD was defined as the dose below the one producing dose limiting toxicity (DLT) in ≥ 2 of 3 to 6 patients. A total of 10 patients were to be treated at the MTD, or highest dose of VPA. The MTD was based on toxicities during the first course of therapy. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria (NCI CTC version 3). The phase II was designed to evaluate the activity of the combination. The study would stop early if the probability was less than 10% that the response rate (CR + CRp) was at least 0.3. We used data based on an overall response rate of 30% observed in the phase I study of single agent low-dose decitabine in this calculation 2 . A maximum of 40 patients could be treated in the phase II. The probability of a patient response was evaluated after every cohort of 10 patients.
The study was to stop if responses were: 0/10, ≤ 3/20, or ≤ 5/30 patients.
Otherwise, the study would accrue a maximum of 40 patients. Patients treated during the phase I portion of the study at the highest dose of VPA who met criteria for the phase II portion were included in the phase II analysis.
Groups were compared with the two-sample t test. In particular, groups were compared with respect to gene methylation by adjusting for baseline methylation of that gene. We anayzed the logarithms of gene methylation levels, since this transformation made the residuals appear more normally distributed. All pvalues are two-sided, and we declared statistical significance if the two-sided pvalue was below 0.05. We did not adjust for multiple comparisons.
Cytogenetic analysis
Cytogenetic analysis was performed in the clinical cytogenetics laboratory at our institution. Baseline cytogenetic analysis was performed prior to therapy, and subsequently with each course of therapy when possible in patients with baseline abnormal cytogenetics only.
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Detection of valproic acid levels
Free and bound VPA levels were measured using commercially available assays. These levels were analyzed on days 0 (prior to therapy), 5 and 10 of each course of therapy.
Isolation of human mononuclear cells
Blood and marrow aspiration specimens from patients and healthy volunteers were drawn into heparin (30 U/ml). Mononuclear cells were separated using 
Analysis of DNA methylation
The following loci and genes were analyzed: LINE, p57KIP2, p15, p73, MDR1 and THBS2. DNA was extracted from patient samples using standard phenolchloroform methods. DNA was modified with sodium bisulfite. Methods for bisulfite modification of DNA and subsequent PCR techniques used in this study are described at http://www3.mdanderson.org/leukemia/methylation, and as previously described 19 . Two different bisulfite PCR assays were used depending on the locus analyzed. For p57KIP2, MDR1 and THBS2, the combined restriction analysis (COBRA) 20 was used as previously described 7, 19 . PCR conditions, primer sequences, GenBank sequence numbers and the restriction enzyme used are shown in Supplemental Information (Supplemental Table 1 
Analysis of histone H3, H4 acetylation and DNA methyltransferase (DNMT1)
Histone H3 and H4 acetylation and DNMT1 were analyzed by Western blot using antibodies directed against acetylated histone H3, H4 or DNMT1. Proteins were extracted using a lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 1 mM PMSF). Thirty µg of protein from each cell lysate were separated in 12% SDS-polyacrylamide gels (Bio-Rad, Hercules, CA) and transferred to Immobilion-P Transfer Membranes (Millipore, Billerica, MA). 
Real-time PCR analysis of mRNA gene expression
Total cellular RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). Two to three µg of total RNA were used for reverse transcription (RT) reactions using the Moloney murine leukemia virus RT enzyme (Invitrogen, Carlsbad, CA).
Levels of p21
CIP1
, and p15 mRNA expression were analyzed using real-time PCR. Primers and probes were purchased from Applied Biosystems and analyzed using an Applied Biosystems Prism 7000 Sequence Detection System 
RESULTS
Study Group
Fifty-four patients were treated. Patient characteristics are shown in Table1.
Twenty-two patients were treated in the phase I, 8 of them were evaluable for both the phase I and II. Two patients treated at the highest dose level of VPA did not meet criteria for the phase II component of the study, as they had less than 10% marrow blasts. Thirty-two patients were treated in the phase II. Eleven (20%) patients older than 60 years had not received prior therapy (Table1).
These patients were not considered candidates for, or refused, intensive chemotherapy.
Valproic acid dose escalation and toxicities observed
Three dose levels of VPA (20, 35 and 50 mg/kg orally daily for 10 days) were studied in combination with a fixed dose of decitabine (15 mg/m 2 IV infused over 1 hour daily x 10 days). No significant non-hematologic toxicities attributable to decitabine were observed at any dose level. The severity of non-hematological drug-related toxicities observed during the first course are shown in Table 2 . No significant toxicities were observed with VPA at 20 mg/kg. With VPA at 35 mg/kg, 2 out of the first 6 patients developed grade 3 neurotoxocity; both were also receiving high doses of other neurotropic agents. After IRB approval, three more patients were treated and no further toxic events were observed. The dose of VPA was escalated to 50 mg/kg. Ten patients were treated at this dose level, and only.
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Clinical activity
Responses are summarized in Table 4 . Of the 54 patients treated, one patient was invaluable for response assessment as he was taken off study because of the presence of the Philadelphia chromosome abnormality, and was changed to imatinib-based therapy. Twelve patients (22%) responded to therapy: 10 CR and 
Cytogenetic responses
Pretreatment cytogenetic characteristics are shown in Supplemental Information (Supplemental Table 1 
Valproic acid levels
Free (mg/L) and bound (ug/ml) VPA acid levels during course 1 of therapy are shown in Table 6 . Non-hematologic toxicity was associated with higher VPA levels: both free and bound day 5 VPA levels were higher in patients who experienced grade 3-4 non-hematological toxicity (free 30.2 in patients without toxicity versus 50 in patients without; bound 103 versus 127.3; p=0.01).
Overall, no association between response and VPA levels was observed when the whole group of patients was analyzed. Median free VPA levels on days 5 and 
DNA methyltransferase 1 levels
Pretreatment DNMT1 protein expression was detected in only 2 out 48 patients and therefore was not informative. In both patients, DNMT1 levels were not detectable by day 1 of therapy ( Figure 2 ).
Analysis of DNA methylation
DNA methylation was analyzed on days 0,1,5,10,21 and 28 of each course of therapy. To assess the effect of decitabine on global DNA methylation, we used the LINE pyrosequencing assay 3 , which was measured in 48 patients. Figure 3 shows the dynamics of LINE hypomethylation with treatment. Levels of LINE methylation declined gradually with therapy to a maximal point coinciding with the last day of treatment, and returned to baseline prior to the next course of therapy. To analyze the effects on gene specific methylation, the following genes were studied: p15, p57KIP2, THBS2, MDR1, p73 (Figure 4) . Table 7 summarizes pretreatment methylation characteristics. Of the 5 genes screened, p15 was the most informative and its methylation was analyzed sequentially on the same days as LINE. Pretreatment p15 methylation was significantly lower in responders (11.4%, range 0-80.9) versus non-responders (22.3%, range 0-59.36), p=0.06. This effect was observed also on days 10 and 28 ( Figure 5 ).
Neither the absolute change in p15 methylation from baseline to day 10 nor the percent change was statistically significant, comparing responders to nonresponders.
Analysis of gene reactivation
The effect on mRNA expression of p15 and p21 CIP1 was evaluated sequentially on the same days studied for methylation. Reactivation of p15 but not of p21 was observed ( figure 6 ). For p15, this effect was proportional to the demethylation of the gene (data not shown). It should be noted that p21 CIP1 is not methylated in leukemia 21 . Gene reactivation was not associated with response.
Subset analysis of pediatric patients
Seven patients (13%) ages 4 to 21 years were treated in this study. All of them had relapsed/refractory AML. Four patients had relapsed after bone marrow transplantation (1 autologous and 3 allogeneic). Three patients that relapsed only.
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Histone acetylation was observed in 14% of patients. No differences in the dynamics of DNA hypomethylation were observed between children and adult patients (data not shown).
DISCUSSION
In this study of low dose decitabine and VPA given for 10 days in patients with advanced leukemia, we defined a safe and effective schedule using decitabine at 15 mg/m 2 IV daily x 10 with VPA at a dose of 50 mg/kg daily also daily for 10 days on the same days as decitabine. Among 53 patients treated, the response rate was 22%, and it was 50% in patients without prior therapy. Induction mortality was very low (2%). This study has defined the MTD of VPA at 50 mg/kg orally daily for 10 days. Our experience suggests that VPA doses above 50 mg/kg for 10 days will be difficult to administer because of frequent grade 2 neurotoxicity, mainly transient confusion and somnolence. This usually peaked by the end of the 10-day course and resolved 1 to 3 days after stopping VPA.
VPA neurotoxicity was enhanced when administered in combination with other neurotropics agents. Such patients, particularly if elderly, should be monitored closely. Further information supporting that a dose of VPA above 50 mg/kg daily only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From for 10 days exceeds the MTD of VPA is derived from an ongoing study of the combination of 5-azacytidine, VPA and ATRA. In this study, a VPA dose of 62.5 mg/kg daily for 7 days was determined to be above the MTD (Garcia-Manero, ongoing). VPA is being used as a single agent in MDS. In the follow-up study of Kuendgen 22 , VPA levels of 50 to 100 ug/ml were targeted. Among 119 patients with low-risk MDS, 1 patient achieved CR, 1 CRp and 23 hematologic improvement. The low rate of CR/CRps in this study is not surprising, as in vitro data indicates that HDAC inhibition is observed at concentrations above 1mM 18 of VPA above the targeted VPA levels of 50 to 100 ug/mL targeted in that study. This is well above levels achievable with VPA at doses used for the treatment of neurological disorders, as targeted in the study of Kuendgen et al. Our study aimed at synergizing the antileukemia activity of decitabine. This was supported by our in vitro model 18 . Our in vitro study also indicated that higher concentrations of VPA were superior to the lower concentrations in terms of synergisms, cytotoxicity and histone acetylation 18 . In this study, VPA levels were directly associated with toxicity but also with clinical activity in previously untreated patients. Of interest, no relationship was observed between histone acetylation and VPA levels, although histone acetylation was more frequent in patients receiving higher doses of VPA. The lack of correlation of VPA levels and histone acetylation may be related to the erratic pharmacokinetics of VPA, the sensitivity of the histone acetylation assays used on this study, the relatively small number of patients treated and the patient's heterogeneity.
only.
The combination of decitabine and VPA induced an overall response rate of 22%, 50% in elderly patients with untreated disease. The treatment mortality was only 1%. Based on our previous experience with high dose cytarabine programs, or more conventional "7+3" programs, this therapy compares well in terms of response and early mortality rates. Whether this activity was influenced by the addition of VPA remains to be determined in comparative trials. Because of the characteristics of the study group, it is difficult to compare it with other studies of decitabine in MDS 1 , but evidence for the benefit of adding VPA to decitabine can be inferred from several observations in this study. First, although an association between higher VPA levels and response was not observed for the whole group of patients, a significant trend was observed when the more homogeneous subset of older untreated patients was analyzed. Second, most responses occurred in those patients receiving higher-doses of VPA. Finally, responses were attained earlier in patients receiving higher doses of VPA: median number of courses to response was 1 for patients receiving higher doses of VPA compared to 2 to 3 courses for patients at the lower dose levels.
The nature of the responses observed was not cosmetic. Responses were robust. The median response duration was 7.2 months. Responders had a median survival of 15.3 months, significantly longer compared to those patients not achieving a response. More importantly, clinical activity was observed in patients with poor-risk cytogenetics, and in those patients, therapy was associated with durable cytogenetic remissions.
This study allowed patients age 2 and older to be registered. The reason for the age restriction is based on data that VPA in younger children (less than 2 years) is associated with significant hepatotoxicity [23] [24] [25] . In this study, the combination of decitabine and VPA was safe in children with advanced relapsed/refractory leukemia. This combination needs to be further explored in childhood leukemia. Because LINE methylation is a normal physiologic phenomenon that occurs both in neoplastic and non-neoplastic cells, the value of the study of the dynamics of global methylation using the LINE assay could be considered a surrogate marker of biological activity of the drug not necessarily related to its clinical activity.
One difficulty in analyzing gene specific methylation in leukemia is its heterogeneity. To circumvent this problem, we used a strategy of screening 5 genes prior to therapy. The most frequently methylated gene, p15, was then monitored sequentially during therapy. Pretreatment p15 methylation levels were lower in patients achieving a response. This suggests that the lower pretreatment p15 methylation levels may identify a subset of patients with good prognosis only.
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The distribution of abnormal karyotypes was similar between both groups of patients. Flt-3 alterations were also evenly distributed between both subgroups (data not shown).
Despite the lack of a correlation between VPA levels and histone acetylation, higher doses of VPA were associated with more frequent induction of both histone H3 and H4 acetylation. This was not associated with a better response rate. A similar phenomenon has been observed in patients treated with single agent vorinostat 26 and with the combination of 5-azacytidine and phenylbutyrate 27 . The lack of association between response and induction of histone acetylation could be explained by the sensitivity of the assays used, or by the possibility that response is related to effects down-stream of histone acetylation, or to acetylation of other proteins not related to histones.
The effect of the combination on gene reactivation was analyzed. An inverse correlation was observed between DNA hypomethylation and reactivation of p15.
Of interest, p21CIP1, a gene invoked to be a key mediator of response to some HDAC inhibitors 28 , was not reactivated in this study.
Decitabine exerts its function by trapping DNA methyltransferase in DNA. In vitro, the use of hypomethylating agents was associated with decreased DNMT protein levels, presumably by trapping of the protein 29 . Using the same assay as Cheng et al 29 , we could only detect DNMT1 levels in a minority of patients prior to therapy. Levels of DNMT1 disappeared upon drug exposure.
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Finally, in this study we were unable to detect a direct relationship between DNA hypomethylation or the induction of histone acetylation and clinical response. As discussed above, this could be explained by several facts. First, the patient population studied here is relatively small and heterogeneous, including both patients with advanced disease and patients with untreated disease. Second, we
are not certain about the sensitivity and specificity of some of the assays used here, in particular for histone acetylation, so it is possible that we may be underdetecting histone acetylation. Third, despite the fact the we studied the methylation dynamics of 5 genes, only one of them, p15, proved to be informative. It is possible that the analysis of methylation of other relevant genes only.
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